New York, June 18, 2026, 12:00 (EDT)
- CDT Equity shares surged on the Nasdaq with strong volume after the company pointed to a fresh private investment in Sarborg.
- CDT said the funding puts a $127.5 million valuation on its Sarborg holding.
- The main risks are still a new convertible loan facility and the upcoming Nasdaq filing-compliance deadline.
CDT Equity Inc. shares surged almost 100% late Thursday morning after the biopharma microcap said its new investment in private company Sarborg Limited points to a far larger value for CDT’s holding in that company. CDT last traded at $1.395, up 101% on the day, with volume topping 190 million shares, according to market data.
CDT said Sarborg’s latest subscription came in at $125,000 per share, giving Sarborg a fully diluted valuation of about $638.3 million. That valuation counts all securities that could turn into shares. CDT holds 1,020 shares, which implies a $127.5 million stake. Chief Financial Officer James Bligh said the fundraising offers “further validation” as Sarborg shifts into quantum computing with SarborgQ. GlobeNewswire
CDT traded at $1.31 on Google Finance at 11:42 a.m. in New York, with a market cap of $6.51 million. Volume for the session hit 188.52 million shares. The 52-week range showed $0.67 to $610.00.
Traders scrambled to reprice the small company as if it matched a private-asset valuation. But that’s not cash in for CDT, and these private marks can swing fast, especially with small or offbeat funding rounds.
Shares moved up two days after CDT said it restructured debt and repaid a $5.74 million convertible note from A.G.P. The company also said it would pay $555,555.56 to Ascent Partners. CEO Andrew Regan said paying down old debt was an “important milestone” and said CDT cut debt by more than $4 million since the start of 2025. GlobeNewswire
CDT’s June 16 SEC filing shows a tougher financing round. The company issued a senior secured convertible promissory note to J.J. Astor & Co., with a $1.971 million principal and $1.46 million coming in before closing fees. CDT gets the funds in two tranches. The filing details 24 weekly payments of $82,125, conversion options tied to how the stock trades, and warrants for 912,500 shares at 72 cents each.
CDT gets some market heat thanks to its SarborgQ tie, but it isn’t grouped with the main quantum-computing stocks. D-Wave, Rigetti and IonQ got a boost earlier this week after a Mizuho report improved the sector’s mood. CDT is exposed through its holding in Sarborg, not directly. The company stays a small health-care outfit.
Timing could raise churn. Nasdaq’s 2026 market holiday calendar has U.S. equity markets shut on Friday, June 19, for Juneteenth, making Thursday the last session before the long break.
But the risk looks clear. The Sarborg number is a private-market figure, not what a real public sale might get. The convertible and warrants could end up diluting holders if converted to shares. CDT said in May that Nasdaq sent a deficiency notice after the late March 10-Q filing. The letter didn’t hit trading right away, but CDT has to give Nasdaq a plan by July 20 if it’s still out of compliance.
Sarborg’s look-through value comes in at $127.5 million, but the public equity is still sitting in the single-digit millions. The stock trades on that gap today. CDT faces its next test: can it get cash, cut licensing deals, or tidy up filings before dilution and compliance issues drag things down again?
